|Articles|January 29, 2015

Pharma 2015: Industry in Flux

Pharma is still a 21st Century growth industry, but investment dynamics no longer favor organic growth. Check out our strategic outlook infographic.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

The challenge for pharmaceutical leaders is not just to become larger but to become more capable—the achievement of which may ultimately define the next era of pharmaceutical competition. Credit: Stock.Adobe.com/wladimir1804

The Merger Paradox: Why Transformational Mergers Create Extraordinary Value and Frequently Fail

ByThani Jambulingam, PhD

August 7th 2026

Inside Pharma's Patent Battleground: The Policy Changes Reshaping Generic and Biosimilar Competition

ByEd Silverman

August 4th 2026

Developing Better Drugs, Not Just More Drugs: Q&A with David Hung

ByMike Hollan,David Hung

July 21st 2026

A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims

ByScott Warren

July 21st 2026

Nuvation Bio’s Global Strategy

ByMike Hollan,David Hung

July 15th 2026

Pharma 2015: Industry in Flux

Related Content

The Merger Paradox: Why Transformational Mergers Create Extraordinary Value and Frequently Fail

Inside Pharma's Patent Battleground: The Policy Changes Reshaping Generic and Biosimilar Competition

Developing Better Drugs, Not Just More Drugs: Q&A with David Hung

A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims

Nuvation Bio’s Global Strategy

Trending on PharmExec

Amazon Pharmacy Launches GLP-1 Delivery Service

Pharmaceutical Executive Daily: Amazon Pharmacy to Offer GLP-1 Delivery Service

Your Questions Answered: The Biggest Pharma Stories of the Week of August 3-7, 2026

Beyond the Megamerger: How Rumored AstraZeneca–BMS Discussions Signal a New Era of Pharmaceutical Competition

FDA Approves Moderna's mRNA-Based Flu Vaccine